Renal Cell Carcinoma

Kidney Cancer

Sumanta Kumar Pal, MD, sheds light on the latest frontline therapeutic options for patients with mRCC and other advancements on the horizon.

Brian I. Rini, MD, professor of medicine at the Cleveland Clinic, discusses the rationale for combining atezolizumab and bevacizumab for patients with metastatic renal cell carcinoma in the IMmotion151trial.

Sunitinib alone was noninferior for median overall survival compared with sunitinib plus cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma, according to findings from the phase III noninferiority CARMENA trial.

Arjun V. Balar, MD, Editor-in-Chief of Targeted Therapies in Oncology, discusses the plenary session at. the 2018 ASCO Annual Meeting. Findings from the CARMENA trial in metastatic clear cell renal cell carcinoma were presented.

General Cancer

Brian I. Rini, MD, discusses atezolizumab and bevacizumab as an effective frontline combination in RCC, as well as PROs with the regimen. 

Charles G. Drake, MD, PhD, director of Genitourinary Oncology at New York Presbyterian/Columbia University Medical Center, discusses his thoughts on whether sunitinib would be more successful as a treatment for patients with renal cell carcinoma if used in the neoadjuvant setting.